This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Cardiovascular disease				
Atherosclerosis	Sphingosine-1-phosphate receptor 2 (S1PR2; S1P2; EDG5)	Studies in mice suggest that inhibiting S1PR2 could help treat atherosclerosis. In a mouse model of atherosclerosis, S1PR2 deficiency or a selective S1PR2 antagonist lowered atherosclerotic plaque formation compared with that in control disease models or that seen using vehicle control. Next steps include identifying more effective and selective inhibitors of the target.	Patent application filed; available for licensing	Wang, F. <i>et al. J. Clin. Invest.</i> ; published online Oct. 18, 2010; doi:10.1172/JCI42315 Contact: Yoh Takuwa, Kanazawa University, Kanazawa, Japan e-mail: ytakuwa@med.kanazawa-u.ac.jp
<i>SciBX</i> 3(42); doi:10.1038/scibx.2010.1265 Published online Oct. 28, 2010				